“We are the vanguard of a revolution towards precision healthcare”

GenomeMe, Canada

GenomeMe is an antibody developer and manufacturer with a focus on Precision Diagnostics. GenomeMe’s product lines include IHC grade antibodies used as companion diagnostics to detect, characterize, and inform treatment options for cancer patients.

GenomeMe is the only company in the world with complete A-Z expertise in antibody development and commercialization. With over 73 hybridoma clones established and commercialized in the past 12 months for diagnostic applications, GenomeMe is fast becoming an industry leader. Our current portfolio includes important diagnostic markers such p16, PD-L1, Her2, IDH1 R132H, and BRAF V600E as well as immunotherapeutic targets such as PD-1, GITR, RORgT, OX-40, OX-40 Ligand, TIM3, CTLA-4, etc.

GenomeMe is at the forefront of a movement to make Precision Medicine a new paradigm for healthcare. The genetic tests and diagnostic kits enable physicians to peer deep into the unique origins of health and disease within each of their patients, radically customizing the healthcare they can deliver.

GenomeMe is at the dawn of a new, genome-empowered era. Join us at the start of this bright new age and make the future of precision medicine begin today.


The newly renovated facility is CAN/CSA ISO 13485:2003 and EN ISO 13485:2012 certified. GenomeMe is currently in the process of acquiring certification by CAP (College of American Pathologists), and DAP (Diagnostic Accreditation Program) to bring the highest standards of safety and quality to every product and service offered no matter where in the world you are.



GenomeMe uses the most powerful DNA sequencing and quantification technologies currently on the market to develop products and services to make tomorrow’s healthcare solutions available today.


  • qPCR Technology
  • Next Generation Sequencing
  • Digital PCR
  • Sanger Sequencing